Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galectin Therapeutics Inc. (GALT : NSDQ)

• Company Description    Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $5.81 Daily Weekly Monthly 20 Day Moving Average: 331,835 shares Shares Outstanding: 64.48 (millions) Market Capitalization: $374.62 (millions) Beta: 0.86 52 Week High: $6.55 52 Week Low: $0.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 34.18% 31.74% 12 Week 40.00% 30.77% Year To Date 350.39% 287.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 - NORCROSS,GA 30071 USA ph: 678-620-3186 fax: 770-864-1327 ir@galectintherapeutics.com http://www.galectintherapeutics.com

• General Corporate Information    Officers Joel Lewis - Chief Executive Officer and President Richard E. Uihlein - Chairman Jack W. Callicutt - Chief Financial Officer Gilbert F. Amelio - Director Benjamin S. Carson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 363225202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 64.48 Most Recent Split Date: 3.00 (0.17:1) Beta: 0.86 Market Capitalization: $374.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -225.32 03/31/25 - -216.05 Current Ratio 09/30/25 - - 06/30/25 - 1.43 03/31/25 - 0.08 Quick Ratio 09/30/25 - - 06/30/25 - 1.43 03/31/25 - 0.08 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -1.89 03/31/25 - -1.81 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©